A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSD UCSF
- Dates
- study startedestimated completion
- Principal Investigator
- by Shumei Kato (ucsd)Adil Daud (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientists at UC Cancer
- Shumei Kato (ucsd)
Assistant Clinical Professor, Medicine. Authored (or co-authored) 62 research publications. - Adil Daud (ucsf)
Immune therapy and Clinical Trials
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT02974725
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated